Foundation and core beliefs
Our Ambition
Neurological disorders are devastating and complex conditions with limited treatment options. By applying our innovative platform technology, we seek to create novel solutions for life-changing therapeutics to patients in medical need.
Our Foundation
Our employees are the foundation for the growth and progress of Contera Pharma. We are agile, ambitious and committed to make a difference for patients. We seek synergies in partnerships and collaborations to accomplish our goals.
Our Science
We are focused on creating a de-risked portfolio of projects aimed at human validated targets. Our scientific capacity and pharma knowledge base serve as strong levers for unraveling both the molecular mechanisms as well as solving the pharmacological challenges in disease.
Recent News
September 27, 2023
Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, and BDD Pharma, a drug delivery company specializing in modified…
Read more
April 11, 2023
Abzu and Contera Pharma expand strategic partnership to add target identification to RNA-therapeutic design platform
Abzu® and Contera Pharma expand their strategic partnership to add drug-target identification to their seminal RNA- and siRNAs therapeutic design platform. Contera…
Read more
Contact us
Contera Pharma Headquarter
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com
